{"organizations": [], "uuid": "371c575628ab768d74802f0981852be00b4adffc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180117.html", "section_title": "Archive News &amp; Video for Wednesday, 17 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-jr-131-long-acting-erythropoiesis/brief-jr-131-long-acting-erythropoiesis-stimulating-agent-demonstrates-equivalence-in-phase-iii-study-idUSL3N1PC2GC", "country": "US", "domain_rank": 408, "title": "BRIEF-JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.927, "site_type": "news", "published": "2018-01-17T14:29:00.000+02:00", "replies_count": 0, "uuid": "371c575628ab768d74802f0981852be00b4adffc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-jr-131-long-acting-erythropoiesis/brief-jr-131-long-acting-erythropoiesis-stimulating-agent-demonstrates-equivalence-in-phase-iii-study-idUSL3N1PC2GC", "ord_in_thread": 0, "title": "BRIEF-JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "kissei pharmaceutical co ltd", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "jcr pharmaceuticals co ltd", "sentiment": "negative"}, {"name": "beijing headline news", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd\n* Says it and JCR Pharmaceuticals Co Ltd jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia\n* In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin\n* Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed\nSource text in Japanese: goo.gl/eXovsF\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/eXovsF"], "published": "2018-01-17T14:29:00.000+02:00", "crawled": "2018-01-18T16:03:05.008+02:00", "highlightTitle": ""}